Marquette Asset Management LLC Sells 26,068 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)

Marquette Asset Management LLC reduced its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 31.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 57,911 shares of the biotechnology company’s stock after selling 26,068 shares during the period. Marquette Asset Management LLC owned 0.08% of Aclaris Therapeutics worth $144,000 as of its most recent SEC filing.

Several other hedge funds have also recently made changes to their positions in ACRS. Trium Capital LLP lifted its position in Aclaris Therapeutics by 1.1% during the 3rd quarter. Trium Capital LLP now owns 1,912,990 shares of the biotechnology company’s stock valued at $2,200,000 after acquiring an additional 20,940 shares during the period. Millennium Management LLC boosted its position in shares of Aclaris Therapeutics by 1.9% in the 2nd quarter. Millennium Management LLC now owns 3,336,850 shares of the biotechnology company’s stock worth $3,671,000 after purchasing an additional 63,358 shares in the last quarter. Geode Capital Management LLC grew its stake in shares of Aclaris Therapeutics by 9.3% in the 3rd quarter. Geode Capital Management LLC now owns 846,446 shares of the biotechnology company’s stock worth $974,000 after buying an additional 72,309 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new position in Aclaris Therapeutics during the 2nd quarter valued at approximately $119,000. Finally, Assenagon Asset Management S.A. purchased a new position in Aclaris Therapeutics during the third quarter valued at $214,000. 98.34% of the stock is owned by hedge funds and other institutional investors.

Aclaris Therapeutics Trading Up 0.8 %

NASDAQ:ACRS opened at $2.50 on Wednesday. The business’s 50-day moving average is $3.09 and its 200 day moving average is $1.91. Aclaris Therapeutics, Inc. has a 12 month low of $0.95 and a 12 month high of $5.17. The company has a market capitalization of $178.58 million, a P/E ratio of -4.81 and a beta of 0.54.

Aclaris Therapeutics (NASDAQ:ACRS) last issued its quarterly earnings data on Wednesday, November 6th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.03). The firm had revenue of $4.35 million for the quarter, compared to analysts’ expectations of $8.31 million. Aclaris Therapeutics had a negative return on equity of 40.26% and a negative net margin of 136.65%. On average, research analysts forecast that Aclaris Therapeutics, Inc. will post -0.75 earnings per share for the current year.

Insider Activity at Aclaris Therapeutics

In other Aclaris Therapeutics news, Director Anand Mehra acquired 666,666 shares of the company’s stock in a transaction on Tuesday, November 19th. The stock was acquired at an average cost of $2.25 per share, with a total value of $1,499,998.50. Following the purchase, the director now directly owns 710,030 shares of the company’s stock, valued at approximately $1,597,567.50. This represents a 1,537.37 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

ACRS has been the subject of several recent analyst reports. Piper Sandler raised shares of Aclaris Therapeutics from a “neutral” rating to an “overweight” rating and lifted their target price for the stock from $3.00 to $13.00 in a report on Monday, November 18th. HC Wainwright upgraded Aclaris Therapeutics from a “neutral” rating to a “buy” rating and set a $20.00 target price on the stock in a research note on Monday, December 23rd. Jefferies Financial Group upgraded Aclaris Therapeutics from a “hold” rating to a “buy” rating and boosted their price target for the stock from $2.00 to $7.00 in a research note on Tuesday, November 19th. Leerink Partners raised Aclaris Therapeutics from a “market perform” rating to an “outperform” rating and increased their price objective for the company from $2.00 to $7.00 in a research report on Tuesday, November 19th. Finally, StockNews.com raised Aclaris Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, November 15th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Aclaris Therapeutics presently has an average rating of “Buy” and a consensus target price of $11.00.

Aclaris Therapeutics Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.